Kura Oncology to Participate in the 9th European Scientific Oncology Conference

LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European Scientific Oncology Conference. Antonio Gualberto, M.D., Ph.D., Chief Medical Officer, will participate and give a presentation entitled “Targeting the RAS-ERK Pathway” on Friday, November 4, 2016. The conference will be held November 3-4, 2016 in Marbella, Spain.

Dr. Gualberto’s slide presentation will be available shortly after the session in the Scientific Presentations and Papers section of Kura Oncology's website at www.kuraoncology.com.

About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.

CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 mark@canalecomm.com

Source:Kura Oncology, Inc.